LIPLASOME PHARMA ApS: Financial statements 2017
CVR: 29428514
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
LIPLASOME PHARMA ApS (CVR 29428514) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -65,000 and a net result of DKK -55,000 compared with DKK -309,000 the year before. Equity in the 2017 report amounted to DKK 33,838,000. The solvency ratio was 88%.
- Gross Profit
- DKK -65,000
- Profit/Loss
- DKK -55,000
- Equity
- DKK 33,838,000
- Total Assets
- DKK 38,473,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | -65 t. | -55 t. | 33.8 mio. | 0 |
| 2016 | - | -328 t. | -309 t. | 33.9 mio. | 0 |
| 2015 | - | -1.7 mio. | -2.5 mio. | 34.2 mio. | 2 |
| 2014 | - | -1.5 mio. | -2.4 mio. | 31.8 mio. | 2 |
| 2013 | - | -1.2 mio. | -147 t. | 34.2 mio. | 2 |
Official annual report
Keep an eye on LIPLASOME PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
LIPLASOME PHARMA ApS has published its annual report for 2016. Gross profit came to DKK -328,000, and the net result was DKK -309,000.
About LIPLASOME PHARMA ApS
LIPLASOME PHARMA ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hans-Henrik Horsted Eriksen. The board consists of John Riis Mortensen (chair), Hans-Henrik Horsted Eriksen and Sanjay Kumar Sehgal. The company is owned by BAGGER-SØRENSEN & CO. A/S. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -28,000 and a net result of DKK 62,000 compared with DKK -36,000 the year before. Equity in the 2025 report amounted to DKK 2,377,000.